Resveratrol treatment restores peripheral insulin sensitivity in diabetic mice in a sirt1-independent manner

Molecular Nutrition and Food Research

Volumn 59, Issue 8, 2015, Pages 1431-1442

  González Rodríguez, Águeda ^a,b,g   Santamaría, Beatriz ^a,b   Mas Gutierrez, José Antonio ^c   Rada, Patricia ^a,b   Fernández Millán, Elisa ^b,d   Pardo, Virginia ^a,b   Álvarez, Carmen ^b,d   Cuadrado, Antonio ^a,b,e   Ros, Manuel ^c   Serrano, Manuel ^f   Valverde, Ángela M ^a,b,e  

^a INSTITUTO DE INVESTIGACIONES BIOMÉDICAS ALBERTO SOLS   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

^c UNIVERSIDAD REY JUAN CARLOS   (Spain)

^d UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^e HOSPITAL UNIVERSITARIO LA PAZ IDIPAZ   (Spain)

^f Centro Nacional de Investigaciones Oncológicas   (Spain)

^g HOSPITAL UNIVERSITARIO SANTA CRISTINA   (Spain)

Author keywords

Hyperglycaemia; Insulin resistance; PTP1B; Resveratrol; Sirt1

Indexed keywords

MUS;

ANTIDIABETIC AGENT; ANTIOXIDANT; ENZYME INHIBITOR; INSULIN RECEPTOR SUBSTRATE; IRS2 PROTEIN, MOUSE; PROTEIN TYROSINE PHOSPHATASE 1B; PTPN1 PROTEIN, MOUSE; RESVERATROL; SIRT1 PROTEIN, MOUSE; SIRTUIN 1; STILBENE DERIVATIVE;

129 MOUSE; ANIMAL; ANTAGONISTS AND INHIBITORS; C57BL MOUSE; COMPARATIVE STUDY; CROSS BREEDING; DIET THERAPY; DIETARY SUPPLEMENT; ENZYMOLOGY; EXPERIMENTAL DIABETES MELLITUS; FEMALE; GENETICS; INSULIN RESISTANCE; KNOCKOUT MOUSE; LIVER; MALE; METABOLISM; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS ISLET; PATHOLOGY; SKELETAL MUSCLE; TRANSGENIC MOUSE;

ANIMALS; ANTIOXIDANTS; CROSSES, GENETIC; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 2; DIETARY SUPPLEMENTS; ENZYME INHIBITORS; FEMALE; HYPOGLYCEMIC AGENTS; INSULIN RECEPTOR SUBSTRATE PROTEINS; INSULIN RESISTANCE; ISLETS OF LANGERHANS; LIVER; MALE; MICE, 129 STRAIN; MICE, INBRED C57BL; MICE, KNOCKOUT; MICE, TRANSGENIC; MUSCLE, SKELETAL; PROTEIN TYROSINE PHOSPHATASE, NON-RECEPTOR TYPE 1; SIRTUIN 1; STILBENES;

EID: 84938556978     PISSN: 16134125     EISSN: 16134133     Source Type: Journal    
DOI: 10.1002/mnfr.201400933     Document Type: Article

References (55)

1. Reusch, J. E., Diabetes, microvascular complications, and cardiovascular complications: what is it about glucose? J. Clin. Invest. 2003, 112, 986-988.
2. LeRoith, D., Beta-cell dysfunction and insulin resistance in type 2 diabetes: role of metabolic and genetic abnormalities. Am. J. Med. 2002, 113 (Suppl 6A), 3S-11S.
3. Dubois, M., Vacher, P., Roger, B., Huyghe, D. et al., Glucotoxicity inhibits late steps of insulin exocytosis. Endocrinology 2007, 148, 1605-1614.
4. Withers, D. J., Burks, D. J., Towery, H. H., Altamuro, S. L. et al., Irs-2 coordinates Igf-1 receptor-mediated beta-cell development and peripheral insulin signalling. Nat. Genet. 1999, 23, 32-40.
5. Withers, D. J., Gutierrez, J. S., Towery, H., Burks, D. J. et al., Disruption of IRS-2 causes type 2 diabetes in mice. Nature 1998, 391, 900-904.
6. Valverde, A. M., Burks, D. J., Fabregat, I., Fisher, T. L. et al., Molecular mechanisms of insulin resistance in IRS-2-deficient hepatocytes. Diabetes 2003, 52, 2239-2248.
7. Gonzalez-Rodriguez, A., Mas Gutierrez, J. A., Sanz-Gonzalez, S., Ros, M. et al., Inhibition of PTP1B restores IRS1-mediated hepatic insulin signaling in IRS2-deficient mice. Diabetes 2010, 59, 588-599.
8. Pandey, K. B., Rizvi, S. I., Biomarkers of oxidative stress in red blood cells. Biomed. Pap. Med. Fac. Univ. Palacky Olomouc Czech Repub. 2011, 155, 131-136.
9. Baur, J. A., Sinclair, D. A., Therapeutic potential of resveratrol: the in vivo evidence. Nat. Rev. Drug Discov. 2006, 5, 493-506.
10. Brasnyo, P., Molnar, G. A., Mohas, M., Marko, L. et al., Resveratrol improves insulin sensitivity, reduces oxidative stress and activates the Akt pathway in type 2 diabetic patients. Br. J. Nutr. 2011, 106, 383-389.
11. Kang, W., Hong, H. J., Guan, J., Kim, D. G. et al., Resveratrol improves insulin signaling in a tissue-specific manner under insulin-resistant conditions only: in vitro and in vivo experiments in rodents. Metabolism 2012, 61, 424-433.
12. Saiko, P., Szakmary, A., Jaeger, W., Szekeres, T., Resveratrol and its analogs: defense against cancer, coronary disease and neurodegenerative maladies or just a fad? Mutat. Res. 2008, 658, 68-94.
13. Lee, S. M., Yang, H., Tartar, D. M., Gao, B. et al., Prevention and treatment of diabetes with resveratrol in a non-obese mouse model of type 1 diabetes. Diabetologia 2011, 54, 1136-1146.
14. Kumar, A., Negi, G., Sharma, S. S., Neuroprotection by resveratrol in diabetic neuropathy: concepts & mechanisms. Curr. Med. Chem. 2013, 20, 4640-4645.
15. Saldanha, J. F., Leal Vde, O., Stenvinkel, P., Carraro-Eduardo, J. C., Mafra, D., Resveratrol: why is it a promising therapy for chronic kidney disease patients? Oxid. Med. Cell. Longev. 2013, 2013, 963217.
16. Baur, J. A., Pearson, K. J., Price, N. L., Jamieson, H. A. et al., Resveratrol improves health and survival of mice on a high-calorie diet. Nature 2006, 444, 337-342.
17. Sun, C., Zhang, F., Ge, X., Yan, T. et al., SIRT1 improves insulin sensitivity under insulin-resistant conditions by repressing PTP1B. Cell Metab. 2007, 6, 307-319.
18. Rodgers, J. T., Lerin, C., Haas, W., Gygi, S. P. et al., Nutrient control of glucose homeostasis through a complex of PGC-1alpha and SIRT1. Nature 2005, 434, 113-118.
19. Haigis, M. C., Guarente, L. P., Mammalian sirtuins-emerging roles in physiology, aging, and calorie restriction. Genes Dev. 2006, 20, 2913-2921.
20. Herranz, D., Munoz-Martin, M., Canamero, M., Mulero, F. et al., Sirt1 improves healthy ageing and protects from metabolic syndrome-associated cancer. Nat. Commun. 2010, 1, 3.
21. Herranz, D., Serrano, M., SIRT1: recent lessons from mouse models. Nat. Rev. Cancer 2010, 10, 819-823.
22. Pfluger, P. T., Herranz, D., Velasco-Miguel, S., Serrano, M., Tschop, M. H., Sirt1 protects against high-fat diet-induced metabolic damage. Proc. Natl. Acad. Sci. USA 2008, 105, 9793-9798.
23. Andersen, G., Burkon, A., Sulzmaier, F. J., Walker, J. M. et al., High dose of dietary resveratrol enhances insulin sensitivity in healthy rats but does not lead to metabolite concentrations effective for SIRT1 expression. Mol. Nutr. Food Res. 2011, 55, 1197-1206.
24. Dao, T. M., Waget, A., Klopp, P., Serino, M. et al., Resveratrol increases glucose induced GLP-1 secretion in mice: a mechanism which contributes to the glycemic control. PLoS One 2011, 6, e20700.
25. Zhang, J., Resveratrol inhibits insulin responses in a SirT1-independent pathway. Biochem. J. 2006, 397, 519-527.
26. Fernandez-Millan, E., de Toro-Martin, J., Lizarraga-Mollinedo, E., Escriva, F., Alvarez, C., Role of endogenous IL-6 in the neonatal expansion and functionality of Wistar rat pancreatic alpha cells. Diabetologia 2013, 56, 1098-1107.
27. Gonzalez-Rodriguez, A., Mas-Gutierrez, J. A., Mirasierra, M., Fernandez-Perez, A. et al., Essential role of protein tyrosine phosphatase 1B in obesity-induced inflammation and peripheral insulin resistance during aging. Aging Cell 2012, 11, 284-296.
28. Li, M., Lu, Y., Hu, Y., Zhai, X. et al., Salvianolic acid B protects against acute ethanol-induced liver injury through SIRT1-mediated deacetylation of p53 in rats. Toxicol. Lett. 2014, 228, 67-74.
29. Schenk, S., McCurdy, C. E., Philp, A., Chen, M. Z. et al., Sirt1 enhances skeletal muscle insulin sensitivity in mice during caloric restriction. J. Clin. Invest. 2011, 121, 4281-4288.
30. Forbes, J. M., Coughlan, M. T., Cooper, M. E., Oxidative stress as a major culprit in kidney disease in diabetes. Diabetes 2008, 57, 1446-1454.
31. Hernandez-Marco, R., Codoner-Franch, P., Pons Morales, S., Del Castillo Villaescusa, C. et al., Oxidant/antioxidant status and hyperfiltration in young patients with type 1 diabetes mellitus. Pediatr. Nephrol. 2009, 24, 121-127.
32. Manna, P., Das, J., Ghosh, J., Sil, P. C., Contribution of type 1 diabetes to rat liver dysfunction and cellular damage via activation of NOS, PARP, IkappaBalpha/NF-kappaB, MAPKs, and mitochondria-dependent pathways: prophylactic role of arjunolic acid. Free Radic. Biol. Med. 2010, 48, 1465-1484.
33. Lee, J. M., Johnson, J. A., An important role of Nrf2-ARE pathway in the cellular defense mechanism. J. Biochem. Mol. Biol. 2004, 37, 139-143.
34. Lagouge, M., Argmann, C., Gerhart-Hines, Z., Meziane, H. et al., Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1alpha. Cell 2006, 127, 1109-1122.
35. Um, J. H., Park, S. J., Kang, H., Yang, S. et al., AMP-activated protein kinase-deficient mice are resistant to the metabolic effects of resveratrol. Diabetes 2010, 59, 554-563.
36. Inada, S., Ikeda, Y., Suehiro, T., Takata, H. et al., Glucose enhances protein tyrosine phosphatase 1B gene transcription in hepatocytes. Mol. Cell Endocrinol. 2007, 271, 64-70.
37. Delibegovic, M., Zimmer, D., Kauffman, C., Rak, K. et al., Liver-specific deletion of protein-tyrosine phosphatase 1B (PTP1B) improves metabolic syndrome and attenuates diet-induced endoplasmic reticulum stress. Diabetes 2009, 58, 590-599.
38. Haj, F. G., Zabolotny, J. M., Kim, Y. B., Kahn, B. B., Neel, B. G., Liver-specific protein-tyrosine phosphatase 1B (PTP1B) re-expression alters glucose homeostasis of PTP1B-/-mice. J. Biol. Chem. 2005, 280, 15038-15046.
39. Seely, B. L., Staubs, P. A., Reichart, D. R., Berhanu, P. et al., Protein tyrosine phosphatase 1B interacts with the activated insulin receptor. Diabetes 1996, 45, 1379-1385.
40. Li, L., Hai, J., Li, Z., Zhang, Y. et al., Resveratrol modulates autophagy and NF-kappaB activity in a murine model for treating non-alcoholic fatty liver disease. Food Chem. Toxicol. 2013, 63, 166-173.
41. Zhang, J., Chen, J., Yang, J., Xu, C. W. et al., Resveratrol attenuates oxidative stress induced by balloon injury in the rat carotid artery through actions on the ERK1/2 and NF-kappa B pathway. Cell Physiol. Biochem. 2013, 31, 230-241.
42. Zabolotny, J. M., Kim, Y. B., Welsh, L. A., Kershaw, E. E. et al., Protein-tyrosine phosphatase 1B expression is induced by inflammation in vivo. J. Biol. Chem. 2008, 283, 14230-14241.
43. Canto, C., Auwerx, J., PGC-1alpha, SIRT1 and AMPK, an energy sensing network that controls energy expenditure. Curr. Opin. Lipidol. 2009, 20, 98-105.
44. White, A. T., McCurdy, C. E., Philp, A., Hamilton, D. L. et al., Skeletal muscle-specific overexpression of SIRT1 does not enhance whole-body energy expenditure or insulin sensitivity in young mice. Diabetologia 2013, 56, 1629-1637.
45. Li, Y., Xu, S., Giles, A., Nakamura, K. et al., Hepatic overexpression of SIRT1 in mice attenuates endoplasmic reticulum stress and insulin resistance in the liver. FASEB J. 2011, 25, 1664-1679.
46. Caron, A. Z., He, X., Mottawea, W., Seifert, E. L. et al., The SIRT1 deacetylase protects mice against the symptoms of metabolic syndrome. FASEB J. 2014, 28, 1306-1316.
47. Purushotham, A., Schug, T. T., Xu, Q., Surapureddi, S. et al., Hepatocyte-specific deletion of SIRT1 alters fatty acid metabolism and results in hepatic steatosis and inflammation. Cell Metab. 2009, 9, 327-338.
48. Wang, R. H., Kim, H. S., Xiao, C., Xu, X. et al., Hepatic Sirt1 deficiency in mice impairs mTorc2/Akt signaling and results in hyperglycemia, oxidative damage, and insulin resistance. J. Clin. Invest. 2011, 121, 4477-4490.
49. Erion, D. M., Yonemitsu, S., Nie, Y., Nagai, Y. et al., SirT1 knockdown in liver decreases basal hepatic glucose production and increases hepatic insulin responsiveness in diabetic rats. Proc. Natl. Acad. Sci. USA 2009, 106, 11288-11293.
50. Banks, A. S., Kon, N., Knight, C., Matsumoto, M. et al., SirT1 gain of function increases energy efficiency and prevents diabetes in mice. Cell Metab. 2008, 8, 333-341.
51. Feige, J. N., Lagouge, M., Canto, C., Strehle, A. et al., Specific SIRT1 activation mimics low energy levels and protects against diet-induced metabolic disorders by enhancing fat oxidation. Cell Metab. 2008, 8, 347-358.
52. Sadi, G., Bozan, D., Yildiz, H. B., Redox regulation of antioxidant enzymes: post-translational modulation of catalase and glutathione peroxidase activity by resveratrol in diabetic rat liver. Mol. Cell Biochem. 2014, 393, 111-122.
53. Zhang, C., Lu, X., Tan, Y., Li, B. et al., Diabetes-induced hepatic pathogenic damage, inflammation, oxidative stress, and insulin resistance was exacerbated in zinc deficient mouse model. PLoS One 2012, 7, e49257.
54. Michan, S., Sinclair, D., Sirtuins in mammals: insights into their biological function. Biochem. J. 2007, 404, 1-13.
55. Ying, W., NAD+ and NADH in cellular functions and cell death. Front Biosci. 2006, 11, 3129-3148.